Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects of enzalutamide and indomethacin and to see
how well they work in treating patients with prostate cancer that does not respond to
treatment with hormones, has come back, or has spread from where it started to other places
in the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using
enzalutamide and indomethacin may fight prostate cancer by lowering the amount of androgen
the body makes and/or blocking the use of androgen by the tumor cells.